{"id":57793,"date":"2024-02-27T18:00:17","date_gmt":"2024-02-27T18:00:17","guid":{"rendered":"https:\/\/medsname.com\/ivabrad\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"ivabrad","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/ivabrad\/","title":{"rendered":"Ivabrad"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Ivabrad?<\/h3>\n

Ivabrad<\/strong> is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer — a selective inhibitor of the If<\/sub> (“funny”) current<\/strong> in the sinoatrial node. Ivabradine was introduced by Servier in 2005 as Procoralan<\/strong> — the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the If<\/sub> current responsible for spontaneous SA node depolarisation. selectively blocks If<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction — it is a “pure” bradycardia agent. Dosing: Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR >60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (>75 yr) start 2.5 mg twice daily. Arrhythmia management is a cardiology-led discipline — diagnosis, drug selection, and monitoring typically require specialist input. This is not a drug for self-initiated therapy.<\/p>\n<\/div>\n

\nMit kapsz a MedsBase-n\u00e1l:<\/strong> WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3 \u00b7 Diszkr\u00e9t csomagol\u00e1s \u00b7 Vil\u00e1gszerte sz\u00e1ll\u00edt\u00e1s \u00b7 1.400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a>\n<\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n

Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n

Generikus gy\u00f3gyszereink WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3kt\u00f3l sz\u00e1rmaznak, \u00e9s diszkr\u00e9t, egyszer\u0171 csomagol\u00e1sban sz\u00e1ll\u00edtjuk \u0151ket vil\u00e1gszerte \u2014 a csomagon nem szerepel a gy\u00f3gyszer neve. A k\u00e1rty\u00e1s fizet\u00e9sek egy szab\u00e1lyozott feldolgoz\u00f3n kereszt\u00fcl t\u00f6rt\u00e9nnek (a sz\u00e1mlale\u00edr\u00e1sok egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t tartalmaznak \u2014 soha nem \u201cMedsBase\u201d vagy b\u00e1rmilyen gy\u00f3gyszer neve). Kriptovalut\u00e1t \u00e9s SEPA banki \u00e1tutal\u00e1st is elfogadunk. Minden rendel\u00e9st a Reshipment Assurance Policy biztos\u00edt\u00e9k fedez.<\/p>\n

What Is Ivabrad?<\/h2>\n

Ivabrad is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Ivabradine was introduced by Servier in 2005 as Procoralan<\/strong> — the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the If<\/sub> current responsible for spontaneous SA node depolarisation.<\/p>\n

How Ivabradine Works<\/h2>\n

Ivabradine selectively blocks If<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction — it is a “pure” bradycardia agent.<\/p>\n

J\u00f3v\u00e1hagyott alkalmaz\u00e1si ter\u00fcletek<\/h2>\n